RHX 317
Alternative Names: RHX-317Latest Information Update: 28 Jul 2022
Price :
$50 *
At a glance
- Originator Rheos Medicines
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Small molecules; Urologics
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Graft-versus-host disease; Lupus nephritis; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 20 Jul 2022 Rheos Medicine files an IND application with the US FDA in US for Autoimmune and Inflammatory disorders prior to July 2022
- 20 Jul 2022 US FDA approves IND application for phase I trial of RHX 317 in Autoimmune and Inflammatory disorders in July 2022
- 20 Jul 2022 Rheos Medicines plans a phase I trial for Autoimmune and Inflammatory diseases (In volunteers) in second half of 2022